期刊文献+

缬沙坦与氨氯地平治疗逆转高血压病左心室肥厚伴心功能不全疗效比较 被引量:3

下载PDF
导出
摘要 目的 对比研究缬沙坦与氨氯地平对治疗高血压病左心室肥厚伴心功能不全及减少临床心血管事件发生的疗效差异。方法  118例高血压伴左室肥厚、心功能不全患者随机分为两组即缬沙坦组 (6 0例 )及氨氯地平组 (5 8例 ) ,缬沙坦组缬沙坦 80mg/d ,氨氯地平组氨氯地平 5mg/d ,疗程为 12个月。治疗前及治疗 6 ,12个月后测量以下指标 :左室舒张末期内径 (LVDd)、室间隔与左室后壁舒张末期厚度 (IVSTd和LVPWTd)、左室重量指数(LVMi)、左室射血分数 (EF)、等容舒张时间 (IRT)、二尖瓣瓣尖处测量舒张早期峰值速度 (E峰 )及舒张晚期峰值速度 (A峰 )、E/A比值。结果 治疗 6个月后两组患者均有逆转左室肥厚 ,改善心功能作用 ,但治疗 12个月后缬沙坦组疗效明显优于氨氯地平组 (P <0 0 5 ) ,各项指标LVDd、IVSTd、LVPWTd、IRT及LVMI均明显降低 ,EF值、E/A明显升高 (P <0 0 5 )。治疗前后对血液电解质、血糖 ,血脂影响差异无显著性 (P >0 0 5 )。结论 缬沙坦较氨氯地平逆转高血压病左室肥厚。
出处 《广东医学》 CAS CSCD 2004年第4期458-460,共3页 Guangdong Medical Journal
  • 相关文献

参考文献20

  • 1Koldas L, Ayan F, Ikifmur B, et al. Short - term effects of rihnenidine on left ventricular hypertrophy and systolic and diastolic function in patients with essential hypertension: comparison with an angiotensin converting enzyme inhibitor and a calcium antagonist. Jpn Heart J, 2003,44(5):693.
  • 2Varagic J, Frohlich ED. Loe.al cardiac renin - angiotensin system: hypertension and cardiac failure. J Mol Cell Can:liol, 2002,34(11 ):1435.
  • 3Carson P, Giles T, Higginbotham M, et al. Angiotensin receptor blockers: evidence for preserving target organs. Clin Cardiol,2001,24(3):183.
  • 4Hack JM, Peters R, Shaft T, et al. Prevention of hypertension and its complications: theoretical basis and guidelines for treatment. J Am Soc Nephrol,2003 14(7 Suppl 2) : S92.
  • 5Zabalgoifia M, Berning J. Impact of coronary artery disease on left ventricular systolic function and geometry in hypertensive patients with left ventricular hypertrophy. Am J Cardiol, 2001,88(6) :646.
  • 6Yamazaki T, Yazaki Y. Molecular mechanism of cardiac hypertrophy and dysfunction. Nippon Rinsho, 1997,55(8) : 1988.
  • 7Latini R, Masson S, Staszewsky L, et al. Valsartan for the trealment of heart failure. Expert Opin Pharmac~her, 2004,5 ( 1 ) : 181.
  • 8Qiu YG, Chen JZ, Zhu JH, et al. Differential effects of moming or evening dosing of arnlodipine on circadian blood pressure and heart rate. Cardiovasc Drugs Ther,2003, 17(4) :335.
  • 9Islim IF, Watson RD, Ihenacho HN, et al. Amlodipine: effective for treatment of mild to moderate essential hypertension and left ventricular hypertrophy. Cardiology,2001,96(Suppl ) : 10.
  • 10Yu G, Liang X, Xie X, et al. Diverse effects of chronic treatment with losartan, fosinopril, and amlodipine on apoptosis, angiotensin Ⅱ in the left ventricle of hypertensive rats. Int J Cardiol, 2001,81 (2 - 3) : 123.

同被引文献27

  • 1侯淑彦,杨朝宽,高恩民,王丽霞.3种剂量血管紧张素转换酶抑制剂对心肌肥厚逆转及对血管紧张素Ⅱ浓度的影响[J].中国实用内科杂志,1996,16(2):93-94. 被引量:9
  • 2吕雄胜,吴绍长,徐梅玉.缬沙坦联合氨氯地平对老年性高血压左心室构型的影响[J].心脑血管病防治,2005,5(6):32-34. 被引量:4
  • 3Chalmers J ,Macmahon S,Mancia G,et al.1999 World Health Organization - International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization[J].Clin Exp Hypertens, 1999,21 (5-6): 1009-1060.
  • 4Yasunari K,Maeda K, Watanabe T,et al.Comparative effects of val- sartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy[J].J Am Coll Cardiol,2004,43(11) :2116-2123.
  • 5Cuspidi C, Sala C, Zanchetti A.Management of hypertension in patients with left ventricular hypertrophy[J].Curr Hypertens Rep, 2007 , 9 (6) : 498-505.
  • 6Solomon S D,Appelbaum E,Manning W J,et al.Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy[J].Circulation, 2009,119(4) : 530-537.
  • 7Devereux R B, Wachtel! K, Gerdts E, et al.Prognostic significance of left ventricular mass change during treatment of hypertension[J].JAMA,2004,292( 19) :2350-2356.
  • 8Narumi H,Takano H,Shindo S,et al.Effects ofvalsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Arnlodipine Randomized Trial[J].Hypertens Res, 2011 ,34 (1) :62-69.
  • 9Takano H,Hasegawa H,Narumi H,et al.Effects of valsartan and arnlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART[J]J Hum Hypertens,2012,26(11):656-663.
  • 10Chalmers J,Macmahon S, Mancia G, et a1.1999 World Health Organization-International Society of Hypertension 6uidelines for the management of hypertension, guidelines sub-committee of the World Health Organization[J].elin Exp Hyperte ns,1999,21(5-6):1009-1060.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部